Academic Journal
The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study
| العنوان: | The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study |
|---|---|
| المؤلفون: | Webb, E.J.D., Howdon, D., Bestwick, R., King, N., Sandoe, J.A.T., Euden, J., Grozeva, D., West, R., Howard, P., Powell, N., Albur, M., Bond, S., Brookes-Howell, L., Dark, P., Hellyer, T., Llewelyn, M., McCullagh, I.J., Ogden, M., Pallmann, P., Parsons, H., Partridge, D., Shaw, D., Szakmany, T., Todd, S., Thomas-Jones, E., Carrol, E.D., Shinkins, B., Sandoe, J., Carrol, E., Henley, J., Maboshe, W., Bargiel, M., Evans, J., Webb, E., Richman, C., Gerver, S., Hope, R., Hopkins, S., Heginbothom, M., Berry, C., Davis, G., Wilkinson, V., Taylor-Barr, E., Brodsky, M., Brown, J., Burns, J., Glynn, S., Gureviciute, A., Howard, M., Kirkpatrick, J., Murphy, H., Richardson, E., Scanlon, D., Small, C., Sweeney, G., Williams, L., Baker, E., Cheema, Y., Dunhill, J., Killick, C., King, C., Kooner, S., Lewis, S., Nash, M., Richardson, O., Tuffney, J., Westacott, C., Williams, S., Cawthron, K., Tai, Y.K., Newman, T., Plowright, M., Shulver, H., Sivakova, A., Ayliffe, F., Darke, E., Fletcher, E., Hammonds, F., Marquez, G., Welch, L., Lee-Milner, J., Spencer, J., Brandao, R., Hrycaiczuk, J., Stanley, J., Cross, E., Hansen, D., Redmore, E., Whyte, A., McCullagh, I., Brown, B., Calabrese, M., Cole, C., DeSousa, J., Dunn, L., Grieveson, S., Gulati, A., Issac, E., Mackay, R., Simoes, F., Apatri, E., Charles, B., Christensen, H., Harvey, A., Lomas, D., Taylor, M., Thomas, V., Walker, D., Howard, L., Joseph, A., Sultan, S., Knox-Macaulay, C., Prestwich, G., Hamilton, R. |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2024 |
| المجموعة: | White Rose Research Online (Universities of Leeds, Sheffield & York) |
| الوصف: | Background Many hospitals introduced procalcitonin (PCT) testing to help diagnose bacterial coinfection in individuals with COVID-19, and guide antibiotic decision-making during the COVID-19 pandemic in the UK. Objectives Evaluating cost-effectiveness of using PCT to guide antibiotic decisions in individuals hospitalized with COVID-19, as part of a wider research programme. Methods Retrospective individual-level data on patients hospitalized with COVID-19 were collected from 11 NHS acute hospital Trusts and Health Boards from England and Wales, which varied in their use of baseline PCT testing during the first COVID-19 pandemic wave. A matched analysis (part of a wider analysis reported elsewhere) created groups of patients whose PCT was/was not tested at baseline. A model was created with combined decision tree/Markov phases, parameterized with quality-of-life/unit cost estimates from the literature, and used to estimate costs and quality-adjusted life years (QALYs). Cost-effectiveness was judged at a £20 000/QALY threshold. Uncertainty was characterized using bootstrapping. Results People who had baseline PCT testing had shorter general ward/ICU stays and spent less time on antibiotics, though with overlap between the groups’ 95% CIs. Those with baseline PCT testing accrued more QALYs (8.76 versus 8.62) and lower costs (£9830 versus £10 700). The point estimate was baseline PCT testing being dominant over no baseline testing, though with uncertainty: the probability of cost-effectiveness was 0.579 with a 1 year horizon and 0.872 with a lifetime horizon. Conclusions Using PCT to guide antibiotic therapy in individuals hospitalized with COVID-19 is more likely to be cost-effective than not, albeit with uncertainty. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text |
| اللغة: | English |
| Relation: | https://eprints.whiterose.ac.uk/215612/1/dkae167.pdf; Webb, E.J.D. orcid.org/0000-0001-7918-839X , Howdon, D., Bestwick, R. et al. (132 more authors) (2024) The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study. Journal of Antimicrobial Chemotherapy, 79 (8). ISSN 0305-7453 |
| DOI: | 10.1093/jac/dkae167 |
| الاتاحة: | https://eprints.whiterose.ac.uk/215612/ https://eprints.whiterose.ac.uk/215612/1/dkae167.pdf https://doi.org/10.1093/jac/dkae167 |
| Rights: | cc_by_4 |
| رقم الانضمام: | edsbas.5BD0151F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/jac/dkae167 |
|---|